Gencore

Gencore is a South Korean biotechnology company specializing in the development of next-generation gene editing technologies. Founded in 2019 by Professor Sangsu Bae, the company focuses on overcoming the delivery and precision limitations of traditional CRISPR/Cas systems. Their proprietary TaRGET (Tiny and Robust Gene Editing Tool) platform utilizes compact gene-editing tools designed for efficient delivery via a single adeno-associated virus (AAV) vector. Gencore's pipeline includes programs for various genetic disorders, such as Leber congenital amaurosis and hereditary tyrosinemia, leveraging base editing and prime editing modalities. The company aims to provide curative treatments for rare genetic diseases through its innovative molecular engineering approach.